ClinicalTrials.gg
TerminatedNCT06063317OASISUpdated Mar 6, 2026

A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)

A Phase 1 interventional study of CF33-CD19 IT Monotherapy and CF33-CD19 IV Monotherapy in Solid Tumor, Adult, sponsored by Imugene Limited. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Imugene Limited · Phase 1, Interventional, and Treatment

Why this study was terminated
Portfolio prioritization

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab and with or without hydroxyurea in adults with advanced or metastatic solid tumors.

Read the detailed description

CF33-CD19, a novel chimeric orthopoxvirus, will be administered as a monotherapy or in combination with blinatumomab and with or without hydroxyurea to assess the safety and efficacy of the treatment regimens as well as immunological changes in the tumour microenvironment.

Subjects eligible for treatment include those with any metastatic or advanced solid tumor who have documented radiological progression per RECIST following at least two prior lines of therapy.

All enrolled monotherapy subjects will be treated with CF33-CD19 on Day 1 and 8 of Cycle 1 and then on Day 1 of each 21-day cycle thereafter. Subjects treated with the combination regimen will receive CF33-CD19 on Days 1 and 15 of each 28-day cycle. In addition, they will receive blinatumomab as a 7-day continuous infusion from Days 2-9 and Days 16-23 of each cycle.

02

Conditions studied

  • Solid Tumor, Adult

Keywords

  • Immunotherapy
  • Oncolytic Virus
  • Bispecific T-Cell Engager
  • BiTE
  • Blincyto
03

In context

Lead sponsor

Imugene Limited is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written from subject or legally authorized representative.
  2. Age ≥ 18 years old on the date of consent.
  3. of at least 3 months.
  4. Any or cytologically confirmed advanced or solid tumor with documented radiological progression per v1.1. Eligible subjects must have received at least two prior lines of approved therapies, including targeted therapies, for which they are eligible and failed or on or after that treatment.
  5. (ECOG) performance status 0 - 1.
  6. At least one as defined by RECIST v1.1 criteria.
  7. Adequate renal function.
  8. Adequate hepatic function.
  9. Adequate hematologic function.
  10. Willing and able to comply with scheduled visits, study treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with a poxvirus based oncolytic virus or a bispecific CD19-directed CD3 T-cell engager.
  2. Continuous systemic treatment with either (>10 mg daily prednisone equivalents) or other medications within 4 weeks prior to first dose of study treatment.
  3. Any radiation within 2 weeks of start of study treatment.
  4. Active disease.
  5. Current or history of severe skin disease with open wounds.
  6. History of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
  7. History of pancreatitis.
  8. Prior allogeneic tissue/organ transplant or other medical conditions requiring ongoing treatment with immunosuppressive drugs or any condition resulting in a systemic immunosuppressed state.
  9. Medical history of central nervous system (CNS) unless the subject has completed definitive treatment for the CNS lesions with whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) and are neurologically stable, asymptomatic, and off corticosteroids for at least 2 months prior to first dose.
  10. History of documented congestive heart failure ( [NYHA] class II - IV), unstable angina, poorly controlled hypertension, valvular heart disease or high-risk uncontrolled arrhythmias.
  11. Bleeding diathesis due to underlying medical condition or ongoing anticoagulation medication.
  12. History or presence of clinically relevant CNS pathology, or any other CNS disability judged by the Investigator to be clinically significant and precluding or participation in the study.
  13. Active infection requiring systemic treatment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    CF33-CD19 IT Administration Monotherapy

    Biological: CF33-CD19 IT Monotherapy

  • Experimental
    CF33-CD19 IV Administration Monotherapy

    Biological: CF33-CD19 IV Monotherapy

  • Experimental
    CF33-CD19 IT Administration in Combination with Blinatumomab

    Biological: CF33-CD19 IT Combination · Drug: Blinatumomab

  • Experimental
    CF33-CD19 IV Administration in Combination with Blinatumomab

    Biological: CF33-CD19 IV Combination · Drug: Blinatumomab

  • Experimental
    CF33-CD19 IT Administration in Combination with Blinatumomab and Hydroxyurea

    Biological: CF33-CD19 IT Combination · Drug: Blinatumomab · Drug: Hydroxyurea

  • Experimental
    CF33-CD19 IV Administration in Combination with Blinatumomab and Hydroxyurea

    Biological: CF33-CD19 IV Combination · Drug: Blinatumomab · Drug: Hydroxyurea

Interventions

  • BiologicalCF33-CD19 IT Monotherapy

    Safety Run-In Phase: CF33-CD19 will be administered intratumorally on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.

  • BiologicalCF33-CD19 IV Monotherapy

    Safety Run-In Phase: CF33-CD19 will be administered intravenously on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.

  • BiologicalCF33-CD19 IT Combination

    Dose Escalation Combination Phase: CF33-CD19 will be administered intratumorally on Days 1 and 15 of each 28 day cycle.

  • BiologicalCF33-CD19 IV Combination

    Dose Escalation Combination Phase: CF33-CD19 will be administered intravenously on Days 1 and 15 of each 28 day cycle.

  • Blinatumomab will be infused via a 7-day continuous infusion from Days 2-9 and Days 16-23 of each 28-day cycle.

  • Hydroxyurea will be orally administered daily.

06

What researchers measure

Primary outcomes

  1. All Treatment Arms - Incidence and severity of Adverse Events

    Adverse events will be graded according to CTCAE v5.0.

    Time frame: From first dose of study drug through 30 days following the last dose of study treatment

  2. Monotherapy Treatment Arms - Determination of the Recommended Phase 2 Dose (RP2D) to apply to Dose Escalation Combination Phase as supported by immune response as seen in lymphocyte subsets

    Change in lymphocyte subset expression in tumor tissue and peripheral blood pre and post dose

    Time frame: From first dose of study drug through treatment discontinuation, an average of 6 months

  3. Monotherapy Treatment Arms - Determination of RP2D to apply to Dose Escalation Combination Phase as supported by immune response as seen in cytokines

    Change in cytokine levels in peripheral blood pre and post dose

    Time frame: From first dose of study drug through treatment discontinuation, an average of 6 months

  4. Monotherapy Treatment Arms - Determination of RP2D to apply to Dose Escalation Combination Phase as supported by anti-tumor activity

    Stable Disease and Response (PR and CR) based on RECIST v1.1 and iRECIST v1.0.

    Time frame: From first dose of study drug through treatment discontinuation, an average of 6 months

Secondary outcomes

  1. Combination Treatment Arms - Determination of the Recommended Phase 2 Dose (RP2D) for CF33-CD19 + blinatumomab + hydroxyurea combination as supported by immune response as seen in lymphocyte subsets

    Change in lymphocyte subset expression in tumor tissue and peripheral blood pre and post dose

    Time frame: From first dose of study drug through treatment discontinuation, an average of 6 months

  2. Combination Treatment Arms - Determination of RP2D for CF33-CD19 + blinatumomab + hydroxyurea combination as supported by immune response as seen in cytokines

    Change in cytokine levels in peripheral blood pre and post dose

    Time frame: From first dose of study drug through treatment discontinuation, an average of 6 months

  3. Combination Treatment Arms - Determination of RP2D for CF33-CD19 + blinatumomab + hydroxyurea combination as supported by anti-tumor activity

    Stable Disease and Response (PR and CR) based on RECIST v1.1 and iRECIST v1.0.

    Time frame: From first dose of study drug through treatment discontinuation, an average of 6 months

  4. All Treatment Arms - Overall Response Rate

    Overall Response Rate (ORR) is defined as the proportion of subjects in the efficacy population who achieve a radiographic Investigator-assessed confirmed CR or PR, per RECIST v1.1 or confirmed iCR or iPR per iRECIST v1.0.

    Time frame: From first dose of study drug through treatment discontinuation, an average of 6 months

  5. All Treatment Arms - Progression Free Survival

    Progression Free Survival (PFS) defined as the time from first dose of study drug to first documentation of PD based on RECIST 1.1, or to death from any cause.

    Time frame: From first dose of study drug through treatment discontinuation, an average of 6 months

  6. All Treatment Arms - Duration of Response

    Duration of Response (DoR) measured as the time from the date a response of PR/iPR or better was first recorded to the date on which progressive disease was first noted or the date of death due to any cause.

    Time frame: From first dose of study drug through treatment discontinuation, an average of 6 months

  7. All Treatment Arms - Disease Control Rate

    Disease Control Rate (DCR), measured as the proportion of subjects who achieve an Investigator-assessed confirmed CR/iCR, PR/iPR, or Stable Disease (SD)/immune SD (iSD) per RECIST v1.1 and iRECIST v1.0.

    Time frame: From first dose of study drug through treatment discontinuation, an average of 6 months

07

Study locations

8 sites
  • City of Hope
    Duarte, California 91010, United States
  • Emory Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Northwestern
    Chicago, Illinois 60208, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14203, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15219, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Feb 2026, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Oct 2, 2023
StartActual
Oct 2, 2023
Primary completionActual
Feb 2, 2026
CompletionActual
Feb 2, 2026
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06063317
Lead sponsor
Imugene Limited
Responsible party
Sponsor
First posted
Oct 2, 2023
Start date
Oct 2, 2023
Primary completion
Feb 2, 2026
Completion
Feb 2, 2026
Last update
Mar 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion